Clinical Trial Update: P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating P1101 in patients with early or overt primary myelofibrosis at low or intermediate-1 risk is currently recruiting, sponsored…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelofibrosis
• Myeloproliferative Neoplasms

Drugs mentioned

• P1101

Snippet

Sponsor: PharmaEssentia | Conditions: Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Status: RECRUITING